Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 88–94 (2005)Cite this article

Abstract

Animal models of sustained ischemia have shown exacerbation of myocardial injury during reperfusion, mediated largely by cytotoxic effects of free radical generation, complement activation, shifts in substrate use and inflammation. On the basis of current understanding of the pathogenesis of reperfusion injury, numerous therapies have shown a reduction in infarct size and improved ventricular function in animal models. Clinical trial experience has, however, so far been disappointing for the use of these therapies in patients with acute myocardial infarction (MI), being associated with no or inconsistent benefit to left-ventricular function, complications of MI or survival. The growing emphasis on early revascularization with primary coronary intervention and stenting in the management acute MI, with the potential for more complete drug delivery to injured myocardium, could provide greater opportunities for pharmacologic cardioprotection as adjunctive therapy in the future.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schomig A et al. (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 343: 385–391

    Article  CAS  Google Scholar 

  2. Montalescot G et al. (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895–1903

    Article  CAS  Google Scholar 

  3. Schomig A et al. (2003) Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 108: 1084–1088

    Article  Google Scholar 

  4. Jennings RB et al. (1990) Development of cell injury in sustained acute ischemia. Circulation 82 (suppl): II2–II12

    CAS  PubMed  Google Scholar 

  5. Neri Serneri GG et al. (2003) Immunomediated and ischemia-independent inflammation of coronary microvessels in unstable angina. Circ Res 92: 1359–1366

    Article  CAS  Google Scholar 

  6. Abbate A et al. (2004) Widespread myocardial inflammation and infarct-related artery patency. Circulation 110: 46–50

    Article  Google Scholar 

  7. Frangogiannis NG et al. (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31–47

    Article  CAS  Google Scholar 

  8. Semenza GL (2000) Cellular and molecular dissection of reperfusion injury: ROS within and without. Circ Res 86: 117–118

    Article  CAS  Google Scholar 

  9. Rezkalla SH and Kloner RA (2002) No-reflow phenomenon. Circulation 105: 656–662

    Article  Google Scholar 

  10. Bialik S et al. (1999) The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 85: 403–414

    Article  CAS  Google Scholar 

  11. Bielawska AE et al. (1997) Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 151: 1257–1263

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Krijnen PAJ et al. (2002) Apoptosis in myocardial ischemia and infarction. J Clin Pathol 55: 801–811

    Article  CAS  Google Scholar 

  13. Zhao ZQ et al. (2000) Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 45: 651–660

    Article  CAS  Google Scholar 

  14. Saraste A et al. (1997) Apoptosis in human acute myocardial infarction. Circulation 95: 320–323

    Article  CAS  Google Scholar 

  15. Olivetti G et al. (1996) Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28: 2005–2016

    Article  CAS  Google Scholar 

  16. Williams RS and Benjamin IJ (2000) Protective responses in the ischemic myocardium. J Clin Invest 106: 813–818

    Article  CAS  Google Scholar 

  17. Murry CE et al. (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136

    Article  CAS  Google Scholar 

  18. Sasaki N et al. (2000) Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101: 439–445

    Article  CAS  Google Scholar 

  19. Jung F et al. (2000) Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 86: 319–325

    Article  CAS  Google Scholar 

  20. Rossig L et al. (1999) Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J Biol Chem 274: 6823–6826

    Article  CAS  Google Scholar 

  21. Moon C et al. (2003) Erythropoietin reduces myocardial infarction and left ventricular decline and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100: 11612–11617

    Article  CAS  Google Scholar 

  22. Parsa CJ et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999–1007

    Article  CAS  Google Scholar 

  23. Radford NB et al. (1996) Cardioprotective effects of 70-kDa heat shock protein transgenic mice. Proc Natl Acad Sci U S A 93: 2339–2342

    Article  CAS  Google Scholar 

  24. Martin JL et al. (1997) Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 96: 4343–4348

    Article  CAS  Google Scholar 

  25. Marber MS et al. (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264–1272

    Article  CAS  Google Scholar 

  26. Hoshida S et al. (1993) Sublethal ischemia alters myocardial antioxidant activity in canine heart. Am J Physiol 33: H33–H39

    Google Scholar 

  27. Braunwald E and Kloner RA (1982) The stunned myocardium: prolonged, post-ischemic ventricular dysfunction. Circulation 66: 1146–1149

    Article  CAS  Google Scholar 

  28. Charlat ML et al. (1989) Prolonged abnormalities of left ventricular diastolic wall thinning in the 'stunned' myocardium in conscious dogs: time course and relation to systolic dysfunction. J Am Coll Cardiol 13: 185–194

    Article  CAS  Google Scholar 

  29. Kloner RA and Jennings RB (2001) Consequences of brief ischemia: Stunning, preconditioning, and their clinical implications. Part 1. Circulation 104: 2981–2989

    Article  CAS  Google Scholar 

  30. Bolli R et al. (1989) Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A 86: 4695–4699

    Article  CAS  Google Scholar 

  31. Przyklenk K and Kloner RA (1986) Superoxide dismutase plus catalase improve contractile function in the canine model of the 'stunned myocardium'. Circ Res 58: 148–156

    Article  CAS  Google Scholar 

  32. Bolli R et al. (2004) Myocardial protection at a crossroads. The need for translation into clinical practice. Circulation 95: 125–134

    Article  CAS  Google Scholar 

  33. Kloner RA and Rezkalla SH (2004) Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J Am Coll Cardiol 44: 276–286

    Article  Google Scholar 

  34. Garratt KN et al. (1998) Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J 136: 196–204

    Article  CAS  Google Scholar 

  35. Mahaffey KW et al. (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarct STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34: 1711–1720

    Article  CAS  Google Scholar 

  36. Quintana M et al. (2003) Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 59: 1–9

    Article  CAS  Google Scholar 

  37. Ross A et al. (2002) Acute Myocardial Infarction STudy of ADenosine (AMISTAD II). J Am Coll Cardiol 39 (Suppl 2): 338A

    Article  Google Scholar 

  38. Kopecky SL et al. (2003) A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 146: 146–152

    Article  CAS  Google Scholar 

  39. Marzilli M et al. (2000) Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101: 2154–2159

    Article  CAS  Google Scholar 

  40. Sodi-Pallares D et al. (1962) Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 9: 166–181

    Article  CAS  Google Scholar 

  41. Fath-Ordoubadi F and Beatt KJ (1997) Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96: 1152–1156

    Article  CAS  Google Scholar 

  42. Diaz R et al. (1998) Metabolic modulation of acute myocardial infarction. The ECLA Glucose-insulin-potassium pilot trial. Circulation 98: 2227–2234

    Article  CAS  Google Scholar 

  43. Van der Horst ICC et al. (2003) Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42: 784–791

    Article  CAS  Google Scholar 

  44. Pache J et al. (2004) A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 48: G1–G6

    Google Scholar 

  45. Rupprecht H-J et al. (2000) Cardioprotective effects of the Na+/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 101: 2902–2908

    Article  CAS  Google Scholar 

  46. Zeymer U et al. (2001) The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) Trial. J Am Coll Cardiol 38: 1644–1650

    Article  CAS  Google Scholar 

  47. Sakata Y et al. (1997) Salutory effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients acute myocardial infarction. Am Heart J 133: 616–621

    Article  CAS  Google Scholar 

  48. Ito H et al. (1999) Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 33: 654–660

    Article  CAS  Google Scholar 

  49. Flaherty JT et al. (1994) Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 89: 1982–1991

    Article  CAS  Google Scholar 

  50. The EMIP-FR Group (2000) Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. A double-blind, placebo-controlled, randomized trial. Eur Heart J 21: 1537–1546

  51. Baran KW et al. (2001) Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study. Circulation 104: 2778–2783

    Article  CAS  Google Scholar 

  52. Faxon DP et al. (2002) The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. J Am Coll Cardiol 40: 1199–1204

    Article  CAS  Google Scholar 

  53. de Zwaan C et al. (2002) Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 23: 1670–1677

    Article  CAS  Google Scholar 

  54. Mahaffey KW et al. (2003) Effect of Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction. The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108: 1176–1183

    Article  CAS  Google Scholar 

  55. Granger CB et al. (2003) Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108: 1184–1190

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Intramural Research, National Heart, Lung, and Blood Institute,

    Richard O Cannon III

  2. Clinical Cardiology Section, Cardiovascular Branch, Bethesda, MD, USA

    Richard O Cannon III

Authors
  1. Richard O Cannon III
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cannon, R. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Rev Cardiol 2, 88–94 (2005). https://doi.org/10.1038/ncpcardio0096

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0096

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing